CFT1946
- Generic Name
- CFT1946
C4 Therapeutics Announces 2025 Milestones for Oncology-Focused Degrader Medicines
• C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma.
• CFT1946, targeting BRAF V600 mutations in solid tumors, is progressing through Phase 1, with data readouts anticipated in the second half of 2025.
• Phase 1 data from CFT8919, aimed at EGFR L858R-mutated non-small cell lung cancer, will inform future development plans outside of China.
• C4 Therapeutics' cash runway is projected to fund operations into 2027, supporting ongoing research and clinical programs.
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in B-Cell Malignancies and Autoimmune Diseases
• Nurix Therapeutics' NX-5948 demonstrates a 75.5% objective response rate in relapsed/refractory CLL/SLL patients in Phase 1 study.
• NX-5948 receives PRIME designation from EMA for CLL and Fast Track designation from FDA for Waldenstrom's Macroglobulinemia.
• Nurix plans to initiate pivotal trials for NX-5948 in CLL and expand development into autoimmune diseases in 2025.
• The company's strong financial position, with $609.6 million in cash, supports aggressive development of its pipeline.
Dana-Farber Cancer Institute Presents Comprehensive Cancer Research at ESMO Congress 2024
• Dana-Farber researchers will present novel cancer treatments, including targeted therapies and antibody-drug conjugates, at the ESMO Congress 2024.
• The DESTINYBreast-12 study will present primary results of trastuzumab deruxtecan in HER2+ advanced/metastatic breast cancer patients with or without brain metastasis.
• The TiNivo-2 Study will present data on tivozanib-nivolumab vs tivozanib monotherapy in renal cell carcinoma patients after prior immune checkpoint inhibitor therapies.
• The SOLARIS study will present data on vitamin D supplementation in metastatic colorectal cancer patients combined with standard chemotherapy plus bevacizumab.
C4 Therapeutics' CFT1946 Shows Promise in BRAF V600 Mutant Solid Tumors
• C4 Therapeutics presented Phase 1 data for CFT1946, a BRAF V600 degrader, at ESMO 2024, showing a well-tolerated safety profile in patients with advanced solid tumors.
• Early data suggests CFT1946 demonstrates dose-dependent bioavailability and successfully degrades BRAF V600E protein, indicating proof of mechanism.
• Initial anti-tumor activity was observed, with some patients achieving partial responses and tumor reductions across various BRAF V600 mutation types.
• The Phase 1 trial continues with expansion cohorts exploring monotherapy and combination approaches, with additional data expected in 2025.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath